Herald Sun + Daily Telegraph | Sofpironium Bromide Story

🗞 MAKING HEADLINES

Herald Sun Reporter, Owen Leonard, met with Botanix executives while they were in Australia this week and has published a story about the Company’s recent acquisition of Sofpironium Bromide.

This novel potential treatment for primary axillary hyperhidrosis, a medical condition that results in excessive underarm sweat, is bringing new hope for sufferers.

Botanix Executive Director, Matthew Callahan, explained why it could fill a market gap:

“At the moment, to treat it, you’ve got a couple of options. You’ve got antiperspirants – covers up the smell but does nothing to actually have an effect on the excessive sweating – and at the other extreme, you’ve got surgery, where they’ll actually go in and cut the nerve to stop the signals getting to the sweat gland to stop you sweating excessively.

“In between, there’s been a lot of drugs that have been around for decades that don’t work very well and have all sorts of nasty side effects.”

Click here to read the story.

Euroz Hartleys Report | ‘Transformational Acquisition’

Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the Company’s recent acquisition of Sofpironium Bromide.

The deal has been called a “transformational acquisition”.

Click here to view the report.

ShareCafe ‘Hidden Gems’ Webinar

Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.

His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.

2022 Edison Open House: Global Healthcare

Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week.

Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for our dermatology and antimicrobial programs.

Click here to register, it’s free.

Last week, the Edison Group also published a quickview analyst report on Botanix Pharmaceuticals, an interesting snapshot of what’s to come for the Company in 2022.

Click here to read the report.

DEAL NEWS | Pfizer enters CBD market

At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone.

Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion.

According to the official press release from Pfizer, ​​Arena holds a ‘diverse and promising’ portfolio, including an innovative CB2 agonist and dermatological disease candidate.

Read the story on Forbes.com

Read the official Pfizer press release

AMR: the next global pandemic?

While the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.” 

At Botanix, we are exploring the potential of synthetic CBD to develop novel therapies to address AMR, and ultimately reduce the dependence on broad-spectrum antibiotics. 

Learn more here.

ANTIMICROBIAL AWARENESS WEEK 18-24 November 2021

According to WHO Director-General Tedros Adhanom Ghebreyesus, antimicrobial resistance is “one of the greatest health threats humanity faces today”.

The Center for Disease Control and Prevention (CDC) estimates that each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. The reality is, #AMR can affect anyone.

At Botanix, we are working proactively to develop alternatives for broad-spectrum antibiotics in the clinic. Our BTX 1801 pipeline is focused on testing the capabilities of synthetic cannabidiol for fighting antibiotic resistance, and to develop a novel platform product for multiple human and animal health applications.

Spread awareness, stop resistance. 

MEET THE TEAM | Lynda Berne, Head of Commercial

With a successful track record of commercialising therapies in the antimicrobial space, and over 18 years of experience in senior commercial leadership within the pharmaceutical sector, Lynda Berne is well equipped to lead the commercial strategy for Botanix’s antimicrobial asset BTX1801.

“BTX1801 is an extremely interesting therapy, as it is the first and only CBD antimicrobial that has shown potent bactericidal activity against gram-positive pathogens with no development of resistance, as well as effective eradication of Staphylococcus aureus in nasal carriers, while maintaining an excellent safety and tolerability profile.”

Lynda is currently collaborating with the clinical team to build the commercial strategy and determine the optimal pathway to market for BTX1801.

“We are evaluating various patient populations at high risk of S. aureus bloodstream infections. This has led us to identify haemodialysis patients who use central venous catheters for dialysis as a population at very high risk of bloodstream infections. 

“There are currently no therapies approved to reduce the risk of bloodstream infections among haemodialysis patients, which creates a significant opportunity for Botanix.” 

Lynda is currently working with health economists and key opinion leaders in nephrology and infectious disease to provide input into Botanix’s clinical trials program and health economic outcomes research plan, with a view to sharing study outcomes with investors and potential partners.

“Our priority right now is to raise awareness of the unmet need and economic burden of bloodstream infections in this population, and to position BTX1801 as the solution.”

4th International Cannabinoid Derived Pharmaceuticals Summit

Botanix is delighted to be attending the 4th International Cannabinoid Derived Pharmaceuticals Summit, being held in Boston this week (21-23 September). 

This is the world’s largest conference devoted exclusively to the production of CBD-derived pharmaceuticals for medical conditions. 

Attending industry-leading conferences provides an invaluable opportunity to network with industry peers and key opinion leaders, and to share updates on our leading CBD-based R&D programs in the space of antimicrobial resistance (AMR) and dermatology. 

Find out more about the conference HERE

Research Report by Euroz Hartleys

Botanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has initiated coverage on Botanix as we lead into an exciting 12 months of clinical studies and corporate activities.

This report reinforces our belief that Botanix has assembled the right people, technology and research strategies to advance our assets, and to deliver positive results for our shareholders and the patients we exist to serve.

Read the full report.